Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12446946 | 0.82 | ABCB1 (0.42) | EPHX2KMT2A | |
| SCHEMBL30921215 | 0.80 | ABCB1 (0.43) | KMT2A | |
| SCHEMBL15167078 | 0.76 | ALDH1A1 (0.54) | POLBALDH1A1PLAUHPNLMNA | |
| SCHEMBL3409968 | 0.76 | NLRP3 (0.46) | — | |
| SCHEMBL27182872 | 0.74 | POLB (0.42) | EPHX2POLBRAB9AALDH1A1PLAU | |
| SCHEMBL10100455 | 0.73 | RECQL (0.46) | EPHX2POLBRAB9AALDH1A1PLAU | |
| SCHEMBL22499173 | 0.72 | ADORA3 (0.43) | EPHX2POLBALDH1A1PLAUHPN | |
| SCHEMBL8396374 | 0.72 | ALDH1A1 (0.44) | EPHX2POLBRAB9AALDH1A1PLAU | |
| SCHEMBL12391278 | 0.72 | ALDH1A1 (0.47) | EPHX2POLBRAB9AALDH1A1EPHX1 | |
| SCHEMBL8392594 | 0.72 | ALDH1A1 (0.44) | EPHX2POLBRAB9AALDH1A1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2292639-B1 | Tubulisine derivatives as anticancer drugs | KEMOTECH S R L (IT) | 2014-09-03 | — | — | EP | disclosed |
| US-8580820-B2 | Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof | KEMTECH S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | KEMOTECH S.r.I (IT) | 2011-08-18 | — | — | US | disclosed |
| EP-2292639-A1 | Tubulisine derivatives as anticancer drugs | Kemotech S.r.l. (IT) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200581-A1 | PHARMACEUTICAL COMPOSITIONS | NR1H3, NR1H2, CCR8 | EPHX2 1797/4885POLB 4236/4885RAB9A 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.